This study is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of LGT209 in hypercholesterolemic patients taking common statin medications and in healthy volunteers.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of subjects (patients and healthy volunteers) with adverse events, serious adverse events and death
Timeframe: 12 weeks
Plasma concentrations of LGT209 following subcutaneous administration
Timeframe: 12 weeks
Change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9) concentration
Timeframe: baseline and 12 weeks
Change from baseline in low density lipoprotein-cholesterol (LDL-C) concentration
Timeframe: baseline and 12 weeks